Get the Stockscreener App
12.74
0.31%
-0.04
Aurinia Pharmaceuticals Inc stock is traded at $12.74, with a volume of 1.37M.
It is down -0.31% in the last 24 hours and up +12.54% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$12.78
Open:
$12.72
24h Volume:
1.37M
Relative Volume:
0.69
Market Cap:
$1.68B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
29.63
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
+2.74%
1M Performance:
+12.54%
6M Performance:
+56.32%
1Y Performance:
+93.62%
1-Day Range:
$12.53
$12.87
1-Week Range:
$12.06
$12.87
52-Week Range:
$6.55
$12.87
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
12.74 | 1.61B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Ieq Capital LLC Invests $266,000 in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Aurinia Pharmaceuticals stock hits 52-week high at 12.82 USD - Investing.com
Jacobs Levy Equity Management Inc. Buys 304,420 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Vident Advisory LLC Acquires New Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Institutional Investors Have a Lot Riding on Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) With 50% Ownership - 富途牛牛
Are Strong Financial Prospects The Force That Is Driving The Momentum In Aurinia Pharmaceuticals Inc.'s NASDAQ:AUPH) Stock? - simplywall.st
Aurinia Pharmaceuticals Inc $AUPH Shares Sold by Invesco Ltd. - MarketBeat
Will Aurinia Pharmaceuticals Inc. bounce back from current supportWeekly Trade Recap & Daily Risk Controlled Trade Plans - Newser
Regression analysis insights on Aurinia Pharmaceuticals Inc. performance2025 Technical Patterns & Growth Focused Stock Pick Reports - Newser
How does Aurinia Pharmaceuticals Inc. compare to its peers2025 Geopolitical Influence & Accurate Intraday Trading Signals - خودرو بانک
Real time alert setup for Aurinia Pharmaceuticals Inc. performanceTrend Reversal & Safe Capital Allocation Plans - Newser
Why is Aurinia Pharmaceuticals Inc. stock going downQuarterly Performance Summary & Expert Approved Trade Ideas - خودرو بانک
Trexquant Investment LP Has $5.63 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Is Aurinia Pharmaceuticals Inc. attractive at current valuationVolume Spike & Fast Moving Stock Trade Plans - خودرو بانک
Can machine learning forecast Aurinia Pharmaceuticals Inc. recoveryEarnings Growth Report & Weekly Breakout Stock Alerts - Newser
Analyzing Aurinia Pharmaceuticals Inc. with risk reward ratio charts2025 Winners & Losers & Free Community Supported Trade Ideas - Newser
Quantitative breakdown of Aurinia Pharmaceuticals Inc. recent move2025 Performance Recap & Advanced Technical Analysis Signals - Newser
Evaluating Aurinia Pharmaceuticals Inc. with trendline analysisPortfolio Growth Summary & Smart Money Movement Tracker - Newser
Using economic indicators to assess Aurinia Pharmaceuticals Inc. potential2025 Trade Ideas & High Win Rate Trade Tips - Newser
Can a trend reversal in Aurinia Pharmaceuticals Inc. lead to recoveryWeekly Profit Analysis & Stepwise Entry and Exit Trade Signals - Newser
Aurinia Pharmaceuticals stock hits 52-week high at 12.55 USD By Investing.com - Investing.com Canada
Armistice Capital LLC Cuts Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Dow Update: What are Aurinia Pharmaceuticals Inc.’s technical support levelsMarket Growth Summary & Real-Time Stock Movement Alerts - خودرو بانک
Full technical analysis of Aurinia Pharmaceuticals Inc. stockWeekly Profit Report & Verified Stock Trade Ideas - Newser
Aurinia Pharmaceuticals stock hits 52-week high at 12.55 USD - Investing.com
Will Aurinia Pharmaceuticals Inc. face regulatory challengesDay Trade & Verified Technical Signals - خودرو بانک
What Fibonacci levels say about Aurinia Pharmaceuticals Inc. rebound2025 Market Overview & Real-Time Volume Analysis Alerts - Newser
Advanced analytics toolkit walkthrough for Aurinia Pharmaceuticals Inc.Bond Market & Smart Investment Allocation Insights - Newser
How to integrate Aurinia Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Drop Watch & Daily Profit Maximizing Trade Tips - Newser
Applying Elliott Wave Theory to Aurinia Pharmaceuticals Inc.July 2025 News Drivers & AI Based Buy/Sell Signal Reports - Newser
Russell Investments Group Ltd. Acquires 72,240 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
Can Aurinia Pharmaceuticals Inc. hit a new high this monthTrade Volume Summary & Daily Chart Pattern Signals - Newser
Aurinia Pharmaceuticals Inc $AUPH Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Is Aurinia Pharmaceuticals Inc. showing insider buyingTrade Volume Report & Stock Timing and Entry Methods - خودرو بانک
How sentiment analysis helps forecast Aurinia Pharmaceuticals Inc.July 2025 Catalysts & Smart Allocation Stock Reports - Newser
Can Aurinia Pharmaceuticals Inc. grow without external fundingWeekly Stock Report & Weekly High Conviction Ideas - خودرو بانک
Visual analytics tools that track Aurinia Pharmaceuticals Inc. performanceJuly 2025 Setups & Daily Volume Surge Trade Alerts - Newser
Should I set a stop loss on Aurinia Pharmaceuticals Inc.Earnings Trend Report & Fast Exit and Entry Strategy Plans - خودرو بانک
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Will Aurinia Pharmaceuticals Inc. benefit from government policyWeekly Market Report & Free Technical Pattern Based Buy Signals - خودرو بانک
Is Aurinia Pharmaceuticals Inc. gaining market share2025 Top Decliners & Low Risk High Win Rate Stock Picks - خودرو بانک
What is Aurinia Pharmaceuticals Inc.’s market position2025 Market WrapUp & Verified Momentum Watchlists - خودرو بانک
Aurinia Pharmaceuticals Inc. stock trend outlook and recovery pathBond Market & Weekly Momentum Stock Picks - Newser
Published on: 2025-09-02 04:45:19 - Newser
Multi factor analysis applied to Aurinia Pharmaceuticals Inc.July 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):